Meet YHLO at 13th International Autoimmunity Congress in Greece
Why could YHLO do all these on diabetes diagnosis?
-
Accurate differential diagnosis between diabetes type 2 and LADA in Adults
-
Accurate prediction of the onset of type 1 diabetes
-
Elimination of lab results discrepancies in interpretation
YHLO achieve it through the cleverly combined interpretation of GADA, IAA, ZnT8A, ICA, and IA-2A!
Please find more about YHLO solutions on diabetes diagnosis...
We will be exhibiting at the #Autoimmunity2022! Join us to know more!
Follow @Autoimmunity2022 to stay updated & we will see you at our booth on 10 –13 June
Attachments:
MORE NEWS
n November 18, 2025, YHLO’s 2025 Global Core Distributors Conference was successfully held in Düsseldorf, Germany. Under the theme “Academia-Driven, Shared Value,” the meeting brought together representatives from more than 30 core distributors worldwide. YHLO’s founder, Mr. Deming Hu, and Chairman, Mr. Kunhui Hu, led the company’s executive team to attend and discuss strategic development with partners.
2025-11-20
YHLO Secures Approval for the World’s First sCD146 CLIA Assay
YHLO has obtained approval from the Guangdong Medical Products Administration for its soluble CD146 (sCD146) CLIA assay, marking a major milestone in central nervous system (CNS) disease diagnostics. YHLO is now the first company worldwide to offer an sCD146 test for cerebrospinal fluid, bringing its total CLIA assay portfolio in China to 173.
2025-11-18
Add: Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, P.R.China
